Village Caregiving reports that frontotemporal dementia is a progressive brain disease affecting behavior, speech, and memory ...

Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the ...

Advanced MRI detects early frontotemporal dementia microstructural damage, enabling earlier diagnosis and monitoring of disease progression.

This represents Alector's second failed neurodegenerative asset in a year, after an AbbVie-partnered asset missed in ...

Alector's Phase 3 trial for FTD-GRN drug, latozinemab, failed the clinical co-primary endpoint. The program is discontinued; ...

A research registry tracking data on a particular form of dementia will be created under a new law sponsored by state Sen.

In the wake of Bruce Willis' diagnosis, Emma Heming has taken to social media to raise awareness about FTD, a type of dementia that affects behavior, personality, and language. Through her heartfelt ...

Alector’s ambitions for a breakthrough in rare dementia have been upended after its lead drug latozinemab (AL001), partnered ...

Alector Inc. cuts its workforce by nearly 50% following the failure of its dementia drug trial, signalling challenges in the ...

Alector Therapeutics is shelving a GSK-partnered antibody after the asset failed to slow disease progression in patients with ...

The immediate consequences of the disappointing result are a big reduction in workforce at South San Francisco-based Alector, ...